Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002602 · ClinicalTrials.gov registry record · Phase 1

Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer

A Phase 1 study of Prostate Cancer, sponsored by Radiation Therapy Oncology Group.

Completed
Registry status
Phase 1
Development phase
1,084
Enrollment target
20
Study locations

NCT00002602 is a Phase 1 study of Prostate Cancer that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 1,084 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (79% higher). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002602, a Phase 1 study of Prostate Cancer, has completed, sponsored by Radiation Therapy Oncology Group.

COMPLETED
Registry status
Phase 1
Development phase
1,084 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for prostate cancer. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy in treating patients who have previously untreated stage II or stage III prostate cancer.

Conditions Studied

Prostate Cancer

Interventions

  • RADIATION 3D-CRT

Study Locations (20)

California

  • Mount Diablo Medical Center - Concord
  • California Cancer Center - Fresno
  • Saint Agnes Cancer Center - Fresno
  • Glendale Memorial Hospital and Health Center - Glendale
  • Sutter Health Western Division Cancer Research Group - Greenbrae
  • Loma Linda University Medical Center - Loma Linda
  • Veterans Affairs Medical Center - Long Beach - Long Beach
  • Kaiser Permanente Medical Center - Los Angeles - Los Angeles
  • USC/Norris Comprehensive Cancer Center - Los Angeles
  • Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
  • Beckman Research Institute, City of Hope - Los Angeles
  • CCOP - Bay Area Tumor Institute - Oakland

Alabama

  • University of Alabama Comprehensive Cancer Center - Birmingham
  • Comprehensive Cancer Institute of Huntsville - Huntsville
  • Mobile Infirmary Medical Center - Mobile
  • MBCCOP - University of South Alabama - Mobile
  • Alabama Oncology, LLC - Montgomery
  • Radiation Oncology Associates of West Alabama - Tuscaloosa

Alaska

  • Providence Cancer Therapy Center - Anchorage

Arizona

  • Arizona Cancer Center - Tucson

Trial Details

FieldValue
Enrollment Target 1,084 participants
Start Date 1994-05
Est. Completion 2013-11
Phase Phase 1

Sponsor

Radiation Therapy Oncology Group

144 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00002602

The ClinicalTrials.gov registry entry for NCT00002602 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1,084 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (79% higher). The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which 3D-CRT is the first listed.

NCT00002602 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Alaska.

Frequently Asked Questions

What is clinical trial NCT00002602 about?

NCT00002602 is a clinical study titled "Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for prostate cancer. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy in treating patients who have previously untreated stage II or stage III prostate cancer.

What is the current status of trial NCT00002602?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 1,084 participants. The study started on 1994-05. Estimated completion is 2013-11.

What conditions does trial NCT00002602 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT00002602?

The interventions under investigation include: 3D-CRT (RADIATION).

Who is sponsoring clinical trial NCT00002602?

This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002602 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.